Co-blockade of immune checkpoints and adenosine A2Areceptor suppresses metastasis.
Immunosuppressive pathways active within the tumor microenvironment must be targeted in combination to sufficiently bolster antitumor immune defenses. Inhibition of A2Aadenosine receptor signaling in combination with immune checkpoint blockade enhances CD8+T and NK cell anti-metastatic activity. This results in reduced metastatic burden and improved survival in pre-clinical models.
Immunology in Cancer and Infection Laboratory and Cancer Immunoregulation and Immunotherapy Laboratories; QIMR Berghofer Medical Research Institute ; Herston, Queensland, Australia ; School of Medicine, University of Queensland ; Herston, Queensland, Australia.
Arabella
A
Young
Immunology in Cancer and Infection Laboratory and Cancer Immunoregulation and Immunotherapy Laboratories; QIMR Berghofer Medical Research Institute ; Herston, Queensland, Australia ; School of Medicine, University of Queensland ; Herston, Queensland, Australia.
Deepak
D
Mittal
Immunology in Cancer and Infection Laboratory and Cancer Immunoregulation and Immunotherapy Laboratories; QIMR Berghofer Medical Research Institute ; Herston, Queensland, Australia.
Kimberley
K
Stannard
Immunology in Cancer and Infection Laboratory and Cancer Immunoregulation and Immunotherapy Laboratories; QIMR Berghofer Medical Research Institute ; Herston, Queensland, Australia.
Michelle
M
Yong
Immunology in Cancer and Infection Laboratory and Cancer Immunoregulation and Immunotherapy Laboratories; QIMR Berghofer Medical Research Institute ; Herston, Queensland, Australia ; School of Medicine, University of Queensland ; Herston, Queensland, Australia.
Michele Wl
MW
Teng
Centre de Recherche du Centre Hospitalier de l'Université de Montréal; Faculté de Pharmacie et Institut du Cancer de Montréal ; Montréal, Québec, Canada.
Bertrand
B
Allard
Centre de Recherche du Centre Hospitalier de l'Université de Montréal; Faculté de Pharmacie et Institut du Cancer de Montréal ; Montréal, Québec, Canada.
John
J
Stagg
Immunology in Cancer and Infection Laboratory and Cancer Immunoregulation and Immunotherapy Laboratories; QIMR Berghofer Medical Research Institute ; Herston, Queensland, Australia ; School of Medicine, University of Queensland ; Herston, Queensland, Australia.
Mark J
MJ
Smyth
PD-1; adenosine; combination therapy; immune checkpoint; metastasis; tumor-mediated immunosuppression